Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 26 to 41 of 41

TitleReference numberPublishedLast updated
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimenTA515
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancerTA509
Intrabeam radiotherapy system for adjuvant treatment of early breast cancerTA501
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancerTA503
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA495
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA496
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxaneTA458
Everolimus with exemestane for treating advanced breast cancer after endocrine therapyTA421
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimensTA423
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancerTA424
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancerTA263
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2TA257
Fulvestrant for the treatment of locally advanced or metastatic breast cancerTA239
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancerTA214
Gemcitabine for the treatment of metastatic breast cancerTA116
Guidance on the use of trastuzumab for the treatment of advanced breast cancerTA34

Results per page

  1. 10
  2. 25
  3. 50
  4. All